Alvotech provides update on FDA action regarding AVT02, proposed high concentration biosimilar to Humira (adalimumab)

20 September 2021 - Alvotech today announced that the FDA is deferring action on the application for AVT02, the company’s proposed ...

Read more →

FDA approves first biosimilar to treat macular degeneration disease and other eye conditions

17 September 2021 - The U.S. FDA today approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the ...

Read more →

Alvotech welcomes positive CHMP opinion for AVT02, a proposed biosimilar to Humira

17 September 2021 - Alvotech today welcomed the positive opinion of the EMA's CHMP recommending the approval of Alvotech‘s high-concentration AVT02 ...

Read more →

CVS juggles biosimilar options on its formulary

27 August 2021 - Whether payers put biosimilars on formulary, versus originator products, depends in large part on the respective ...

Read more →

PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding

26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February ...

Read more →

Avastin biosimilar may bring insurance benefits for Tecentriq

25 August 2021 - The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns ...

Read more →

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

23 August 2021 - Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the ...

Read more →

Ophthalmologist group wants U.S. Government to push back against Avastin biosimilars

10 August 2021 - The American Academy of Ophthalmology says biosimilar alternatives to Avastin have never been tested in the ...

Read more →

Barriers to US biosimilar market growth: lessons from biosimilar patent litigation

6 August 2021 - High biologic drug prices have placed substantial strain on the US health care system.  ...

Read more →

Competition from biosimilars drives price reductions for biologics in the French single payer health system

6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...

Read more →

Formycon and Bioeq announce submission of the biologics license application for FYB201, a biosimilar candidate to Lucentis (ranibizumab) to the U.S. FDA

5 August 2021 - Formycon and its license partner Bioeq announce that the biologics license application for FYB201, Formycon’s biosimilar ...

Read more →

FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

28 July 2021 - Availability of insulin products will help increase access and potentially lower the cost of insulin for people ...

Read more →

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

27 July 2021 - In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a ...

Read more →

Sorrento announces its partner Mabpharm has received marketing approval in China for infliximab biobetter

20 July 2021 - Sorrento to exclusively market the product outside of China including US, Japan and Europe. ...

Read more →

Formycon and Bioeq announce submission of the marketing authorisation application for FYB201, a biosimilar candidate to Lucentis (ranibizumab) to the EMA

29 June 2021 - Formycon and its license partner Bioeq AG announce that the marketing authorisation application for FYB201, Formycon’s ...

Read more →